Study S002127

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

ClinicalTrials.gov record

Registration

Registration: NCT07035093
Acronym: TRIUMPH-7
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 586
Start: 2025-05-29
Primary completion: 2027-09
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight; Chronic Low Back Pain (CLBP)
Interventions: DRUG:Retatrutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J1I-MC-GZQD; CTIS:2024-517431-43-00

Registered primary outcomes

Change from Baseline in Pain Intensity Per Numeric Rating Scale [Baseline, up to 72 weeks]
Percent Change from Baseline in Body Weight [Baseline, up to 72 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.